Drug recall · November 5, 2014
Carbamazepine Tablets USP recall
Why: Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for the Carbamazepine API final intermediate was pending approval.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Carbamazepine Tablets USP, 200 mg, 1000 Tablets per Bottle, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 26110 Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4005-3.
- Lots / codes
Lot 137393, exp. 10/2016
- Quantity
- 1,966 bottles
- Company
- Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY
- Distribution
- IL, OH, LA
- Initiated
- October 21, 2014 · Voluntary: Firm initiated
- Classified
- October 27, 2014
- Reported
- November 5, 2014
- Ended
- April 3, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Carbamazepine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.